Case number
|
IFAT
|
Blood
|
Lymph-node
|
Lymph-node in-vitro culture
|
Conjunctival swab
|
Oral swab
|
DTH
|
DTH
|
---|
| |
PCR ( Leishmania/mL)
|
PCR ( Leishmania/sample)
| | |
PCR ( Leishmania/sample)
|
48 h (cm)
|
72 h (cm)
|
---|
| | | | |
PCR ( Leishmania/sample)
| | | |
---|
1
|
-
|
-
|
-
|
NP
|
NP
|
NP
|
2,50#
|
1,75#
|
2
|
-
|
-
|
-
|
-
|
NP
|
NP
|
NP
|
NP
|
3
|
-
|
-
|
-
|
-
|
NP
|
NP
|
3,00#
|
3,25#
|
4
|
-
|
-
|
-
|
NP
|
-
|
NP
|
1,60#
|
1,75#
|
5
|
1:80
|
-
|
-
|
-
|
+ (5)
|
-
|
2,25*
|
1,15*
|
6
|
-
|
-
|
-
|
-
|
+ (10)
|
-
|
1,25*
|
2,00*
|
7
|
-
|
-
|
-
|
-
|
-
|
-
|
NP
|
NP
|
8
|
-
|
-
|
-
|
-
|
+ (70)
|
+ (3)
|
1,50*
|
1,25*
|
9
|
-
|
-
|
-
|
-
|
+ (20)
|
-
|
1,00*
|
0,00*
|
10
|
-
|
-
|
-
|
-
|
-
|
-
|
1,50*
|
1,75*
|
11
|
1:160
|
-
|
-
|
-
|
-
|
-
|
NP
|
NP
|
12
|
-
|
-
|
-
|
NP
|
-
|
-
|
NP
|
NP
|
13
|
1:80
|
-
|
-
|
NP
|
NP
|
NP
|
NP
|
NP
|
14
|
1:320
|
-
|
-
|
NP
|
NP
|
NP
|
NP
|
NP
|
15
|
1:320
|
-
|
-
|
NP
|
NP
|
NP
|
NP
|
NP
|
16
|
-
|
-
|
+ (6)
|
NP
|
NP
|
NP
|
NP
|
NP
|
17
|
-
|
-
|
-
|
NP
|
NP
|
NP
|
NP
|
NP
|
Total number of positive results/total number of dogs studied (%)
|
5/17 (29.4%)
|
0/17 (0%)
|
1/17 (5.8%)
|
0/9 (0%)
|
4/9 (44.4%)
|
1/8 (12.5%)
| |
- + positive; −: negative; NP: not performed; l/sample: Leishmania/sample; *DTH results upon clinical presentation and in some cases # at follow up.